EMA and FDA set common principles for AI in medicine development - ema.europa.eu
EMA and FDA have established common principles for the use of AI in medicine development, impacting regulatory expectations for pharmaceutical companies.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical manufacturers involved in drug development utilizing AI technologies. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing compliance as principles are implemented.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New common principles for AI in medicine development set by EMA and FDA, affecting compliance and operational protocols.
Who it affects
All pharmaceutical manufacturers involved in drug development utilizing AI technologies.
What you must do
Review and adjust AI development processes to align with the new principles set by EMA and FDA.
Deadline
Ongoing compliance as principles are implemented.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- DOJ Moves FDA Approved and Medical Marijuana to Schedule III - ArentFox Schiff
- The FDA no longer requires all drugs to be tested on animals before human trials - opb.org
- FDA Selects Seven Companies for Drug Manufacturing Pilot - themedicinemaker.com
- U.S. signals crackdown on compounded weight-loss drugs; Hims shares tumble - CNBC
- US FDA launches program to boost domestic drug manufacturing - reuters.com